RxDoctor Payments Data

Carlos Borge

Child & Adolescent Psychiatry · Sarasota, FLNPI 1881715316

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (49.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Ironshore Pharmaceuticals Inc. at 33.6% of the total. Reporting peaked in 2019 at $10,507 and has fallen 89.7% since, to $1,082 in 2025. Among child & adolescent psychiatry clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,631in general payments, 2019–2025

Across 89 payments — averaging $164.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ironshore Pharmaceuticals Inc.$5K
  • Takeda Pharmaceuticals U.S.A., Inc.$4K
  • AbbVie$736
  • Johnson & Johnson$734
  • Neurocrine Biosciences, Inc.$694
  • Axsome Therapeutics, Inc.$589
  • plus $3K from 12 others

What the payments were for

  • Speaking & faculty fees$7,20049%
  • Travel & lodging$1,42710%
  • Food & beverage$5,83840%
  • Education$1651%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,631 in reported general payments places this provider in the 95th percentile of 206 child & adolescent psychiatry providers in Florida.

See all child & adolescent psychiatry providers in Florida

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl17$23,199
TrintellixVortioxetine Hydrobromide23$10,732
Desvenlafaxine Succinate ErDesvenlafaxine Succinate167$8,698
Olanzapine-Fluoxetine HclOlanzapine/Fluoxetine Hcl25$7,797
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine169$6,703
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine83$4,923
Lisdexamfetamine Dimesylate15$4,831
Clonazepam395$4,031
Paliperidone ErPaliperidone12$3,519
Aripiprazole112$2,921
Gabapentin123$2,499
Alprazolam218$2,381
Lurasidone Hcl15$2,099
Clorazepate Dipotassium13$1,963
Lamotrigine171$1,824

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$736$23,19917 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$4,428$10,73223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 206 child & adolescent psychiatry providers in Florida.

Other child & adolescent psychiatry in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →